Marker Therapeutics (MRKR) Capital Expenditures (2018 - 2023)

Marker Therapeutics (MRKR) has 6 years of Capital Expenditures data on file, last reported at $141979.0 in Q1 2023.

• Capital Expenditures for Q1 2023 came in at $141979.0, down 93.9% year-over-year; the trailing twelve-month figure through Mar 2023 was -$2.1 million (down 149.87% YoY), and the FY2022 annual result was $57607.0, down 97.33% from the prior year.
• Capital Expenditures grew to $141979.0 in Q1 2023 per MRKR's latest filing, from -$24691.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $2.5 million in Q2 2020 and troughed at -$2.3 million in Q2 2022.
• A 5-year average of $236041.8 and a median of $66170.0 in 2022 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2020 and 2022: Capital Expenditures surged 1233.58% in 2020, then tumbled 3741.79% in 2022.
• A 5-year view of Capital Expenditures shows it stood at -$223126.0 in 2019, then tumbled by 220.28% to -$714619.0 in 2020, then jumped by 392.51% to $2.1 million in 2021, then slumped by 101.18% to -$24691.0 in 2022, then surged by 675.02% to $141979.0 in 2023.
• Business Quant data shows MRKR's Capital Expenditures at $141979.0 in Q1 2023, -$24691.0 in Q4 2022, and $66170.0 in Q3 2022.